Ballicules › Drugs › Trihexyphenidyl
What it is Central antimuscarinic; drug-induced parkinsonism, dystonia and tremor.
Why this one It is effective for dystonia, including the primary dystonias, where few oral agents work.
What limits it Anticholinergic burden and cognitive impairment, so it is poor in the elderly. It does not help tardive dyskinesia and can worsen it.
FDA-approved for
Parkinson disease / drug-induced EPS (1949)
Off-label
FDA label
Read the full label on DailyMed ↗
FDA dosing Population Start Target Max
Idiopathic parkinsonism Adults 1 mg on day 1 6–10 mg/day 12–15 mg/day (postencephalitic)
Drug-induced extrapyramidal reactions Adults 1 mg 5–15 mg/day 15 mg/day
Titration Increase by 2 mg increments every 3 to 5 days (parkinsonism)
Renal Undefined
Hepatic Undefined
Instructions Individualize; start low, especially in patients over 60 years Give before or after meals per patient tolerance Divide daily dose into 3 (at mealtimes); doses >10 mg/day into 4 (add a bedtime dose) With levodopa, reduce the dose of each (usually 3–6 mg/day trihexyphenidyl)
Cautions Anticholinergic effects (dry mouth, blurred vision, urinary retention, tachycardia, mydriasis) Angle-closure glaucoma reported with long-term use Mental confusion, agitation, hallucinations — especially with arteriosclerosis or in the elderly Constipation, dilation of colon, paralytic ileus Potential for abuse (euphoria) with overdosage Suppurative parotitis from excessive dry mouth
Adverse reactions Dry mouth Blurred vision Dizziness Mild nausea Nervousness Constipation Drowsiness Urinary hesitancy/retention Tachycardia
Pregnancy Undefined
Lactation Undefined
Principal risk Anticholinergic burden and cognitive impairment
Cost, est. cash $5–$150/month
Generic entry 1982
Classes and tags
Clinical profile
Therapeutic safety burden 1 / 4
Overdose danger 1 / 4
Weight-gain liability 0 / 4
Sedation liability 1 / 4
QT / Torsades 0 / 4
Direct muscarinic antagonism 4 / 4
Embryofetal risk 1 / 4
Legacy pregnancy category C
Defining liability Generally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.
Mechanism of action: Trihexyphenidyl ballicule
Open Trihexyphenidyl in the interactive console ↗
Memory aids: mascots and interaction avatars
“Triangle-hexagon Art thing” “mad as a hatter” → BBB-crossing antimuscarinic
Box: minimal PK interactions
Open Trihexyphenidyl in the interactive console ↗